Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide
1.0.0-ballot3 - STU 1 ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
| Page standards status: Informative |
<Composition xmlns="http://hl7.org/fhir">
<id value="236951"/>
<meta>
<versionId value="111"/>
<lastUpdated value="2026-06-08T13:51:22.449Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/summary-of-findings"/>
</meta>
<language value="en"/>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Composition 236951</b></p><a name="236951"> </a><a name="hc236951"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 111; Last updated: 2026-06-08 13:51:22+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-summary-of-findings.html">SummaryOfFindings</a></p></div><p><b>Artifact Description</b>: </p><div><p>Example of SummaryOfFindings Profile for Evidence Based Medicine on FHIR Implementation Guide</p>
</div><p><b>ArtifactPublicationStatus</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/cited-artifact-status-type active}">Active</span></p><p><b>url</b>: <a href="https://fevir.net/resources/Composition/236951">https://fevir.net/resources/Composition/236951</a></p><p><b>identifier</b>: FEvIR Object Identifier/236951, FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/179423 SummaryOfFindings}">Summary of Findings</span></p><p><b>date</b>: 2026-06-08 13:51:22+0000</p><p><b>author</b>: Qiukui Hao</p><p><b>title</b>: SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes</p><p><b>custodian</b>: <a href="Organization-118079.html">Computable Publishing LLC</a></p><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Part Of</p><p><b>target</b>: MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-conversion-report)</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Part Of</p><p><b>target</b>: ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes (Identifier: FEvIR Linking Identifier/MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798)</p></blockquote><blockquote><p><b>relatesTo</b></p><p><b>type</b>: Cite As</p><p><b>target</b>: </p><div><p>SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2026-06-08. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json.</p>
</div></blockquote></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-description">
<valueMarkdown
value="Example of SummaryOfFindings Profile for Evidence Based Medicine on FHIR Implementation Guide"/>
</extension>
<extension
url="http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status">
<valueCodeableConcept>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/cited-artifact-status-type"/>
<code value="active"/>
<display value="Active"/>
</coding>
</valueCodeableConcept>
</extension>
<url value="https://fevir.net/resources/Composition/236951"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net/FOI"/>
<value value="236951"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-summary-of-findings-85394-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="SummaryOfFindings"/>
<display value="SummaryOfFindings"/>
</coding>
<text value="Summary of Findings"/>
</type>
<date value="2026-06-08T13:51:22.449Z"/>
<author>
<display value="Qiukui Hao"/>
</author>
<title
value="SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
<custodian>🔗
<reference value="Organization/118079"/>
<type value="Organization"/>
<display value="Computable Publishing LLC"/>
</custodian>
<relatesTo>
<type value="part-of"/>
<targetReference>
<type value="Composition"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-conversion-report"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGICapp Conversion Report: SGLT2 inhibitors and GLP-1 RA for type 2 diabetes"/>
</targetReference>
</relatesTo>
<relatesTo>
<type value="part-of"/>
<targetReference>
<type value="Composition"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-comparative-evidence-report-85394-85798"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="ComparativeEvidenceSynthesisReport: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</targetReference>
</relatesTo>
<relatesTo>
<type value="cite-as"/>
<targetMarkdown
value="SummaryOfFindings: SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes [Database Entry: FHIR Composition Resource]. Contributors: Qiukui Hao [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 236951. Revised 2026-06-08. Available at: https://fevir.net/resources/Composition/236951. Computable resource at: https://fevir.net/resources/Composition/236951#json."/>
</relatesTo>
<section>
<title value="Column Headers"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="column-headers"/>
<display value="Column Headers"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No narrative text.]</p></div>
</text>
<section>
<title value="Outcome Measure"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Outcome</p></div>
</text>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Sample Size</p></div>
</text>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Result Without Treatment</p></div>
</text>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Result With Treatment (Observed)</p></div>
</text>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Result With Treatment (Calculated)</p></div>
</text>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Effect Estimate</p></div>
</text>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Certainty of Evidence</p></div>
</text>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What this means</p></div>
</text>
</section>
</section>
<section>
<title value="Summary of Findings"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings"/>
<display value="Summary of Findings"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<section>
<title value="All-cause mortality"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236953"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313956"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: All-cause mortality"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>All-cause mortality</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236953"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313956"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: All-cause mortality"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>2 studies, 1282 participants</p></div>
</text>
<entry>
<reference value="Evidence/557343"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>24.1%</p></div>
</text>
<entry>
<reference value="Evidence/557345"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>21.8%</p></div>
</text>
<entry>
<reference value="Evidence/557344"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: All-cause mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>21.84%</p></div>
</text>
<entry>
<reference value="Evidence/557345"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: All-cause mortality in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557343"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference -2.3% (CI95 -4.0% to -0.4%); OR 0.88 (CI95 0.79 to 0.98)</p></div>
</text>
<entry>
<reference value="Evidence/557343"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Moderate certainty -- Due to serious imprecision</p></div>
</text>
<entry>
<reference value="Evidence/557343"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SGLT2 inhibitors probably reduce the risk of all cause mortality compared with GLP-1 receptor agonists.</p></div>
</text>
<entry>
<reference value="Evidence/557343"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313956-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: All-cause mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Cardiovascular mortality"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236956"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313957"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Cardiovascular mortality"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Cardiovascular mortality</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236956"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313957"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Cardiovascular mortality"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1 studies, 463 participants</p></div>
</text>
<entry>
<reference value="Evidence/557346"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>15.7%</p></div>
</text>
<entry>
<reference value="Evidence/557348"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>15.2%</p></div>
</text>
<entry>
<reference value="Evidence/557347"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Cardiovascular mortality in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>15.17%</p></div>
</text>
<entry>
<reference value="Evidence/557348"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Cardiovascular mortality in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557346"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference -0.5% (CI95 -2.2% to 1.2%); OR 0.96 (CI95 0.84 to 1.09)</p></div>
</text>
<entry>
<reference value="Evidence/557346"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Moderate certainty -- Due to serious imprecision</p></div>
</text>
<entry>
<reference value="Evidence/557346"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>
</text>
<entry>
<reference value="Evidence/557346"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313957-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Cardiovascular mortality with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Nonfatal myocardial infarction"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236959"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313958"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Nonfatal myocardial infarction"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Nonfatal myocardial infarction</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236959"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313958"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Nonfatal myocardial infarction"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1 studies, 463 participants</p></div>
</text>
<entry>
<reference value="Evidence/557349"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>17.7%</p></div>
</text>
<entry>
<reference value="Evidence/557351"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>17%</p></div>
</text>
<entry>
<reference value="Evidence/557350"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Nonfatal myocardial infarction in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>16.97%</p></div>
</text>
<entry>
<reference value="Evidence/557351"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Nonfatal myocardial infarction in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557349"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference -0.7% (CI95 -2.4% to 1.1%); OR 0.95 (CI95 0.84 to 1.08)</p></div>
</text>
<entry>
<reference value="Evidence/557349"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Moderate certainty -- Due to serious imprecision</p></div>
</text>
<entry>
<reference value="Evidence/557349"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of nonfatal myocardial infarction.</p></div>
</text>
<entry>
<reference value="Evidence/557349"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313958-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal myocardial infarction with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Nonfatal stroke"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236962"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313959"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Nonfatal stroke"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Nonfatal stroke</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236962"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313959"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Nonfatal stroke"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>2 studies, 1282 participants</p></div>
</text>
<entry>
<reference value="Evidence/557352"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>16.5%</p></div>
</text>
<entry>
<reference value="Evidence/557354"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>19.2%</p></div>
</text>
<entry>
<reference value="Evidence/557353"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Nonfatal stroke in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>19.17%</p></div>
</text>
<entry>
<reference value="Evidence/557354"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Nonfatal stroke in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557352"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference 2.7% (CI95 0.4% to 5.3%); OR 1.2 (CI95 1.03 to 1.41)</p></div>
</text>
<entry>
<reference value="Evidence/557352"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Moderate certainty -- Due to serious imprecision</p></div>
</text>
<entry>
<reference value="Evidence/557352"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p> SGLT2 inhibitors probably increase the risk of nonfatal stroke compared with GLP-1 receptor agonists.</p></div>
</text>
<entry>
<reference value="Evidence/557352"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313959-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Nonfatal stroke with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="End-stage kidney disease"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236965"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313960"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: End-stage kidney disease"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>End-stage kidney disease</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236965"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313960"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: End-stage kidney disease"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1 studies, 463 participants</p></div>
</text>
<entry>
<reference value="Evidence/557355"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>11.9%</p></div>
</text>
<entry>
<reference value="Evidence/557357"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>10.9%</p></div>
</text>
<entry>
<reference value="Evidence/557356"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: End-stage kidney disease in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>10.95%</p></div>
</text>
<entry>
<reference value="Evidence/557357"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: End-stage kidney disease in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557355"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference -1.0% (CI95 -3.4% to 2.0%); OR 0.91 (CI95 0.69 to 1.2)</p></div>
</text>
<entry>
<reference value="Evidence/557355"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Moderate certainty -- Due to serious imprecision</p></div>
</text>
<entry>
<reference value="Evidence/557355"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There probably be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists.</p></div>
</text>
<entry>
<reference value="Evidence/557355"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313960-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: End-stage kidney disease with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Heart failure"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236968"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313961"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Heart failure"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Heart failure</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236968"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313961"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Heart failure"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No sample size data.]</p></div>
</text>
<entry>
<reference value="Evidence/557358"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>22.4%</p></div>
</text>
<entry>
<reference value="Evidence/557360"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>17.6%</p></div>
</text>
<entry>
<reference value="Evidence/557359"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Heart failure in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>17.6%</p></div>
</text>
<entry>
<reference value="Evidence/557360"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Heart failure in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557358"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference -4.8% (CI95 -6.6% to -2.7%); OR 0.74 (CI95 0.65 to 0.85)</p></div>
</text>
<entry>
<reference value="Evidence/557358"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>High certainty</p></div>
</text>
<entry>
<reference value="Evidence/557358"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SGLT2 inhibitors reduce the risk of heart failure compared with GLP-1 receptor agonists.</p></div>
</text>
<entry>
<reference value="Evidence/557358"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313961-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Heart failure with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Diabetic ketoacidosis"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236971"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313962"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Diabetic ketoacidosis"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Diabetic ketoacidosis</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236971"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313962"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Diabetic ketoacidosis"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1 studies, 463 participants</p></div>
</text>
<entry>
<reference value="Evidence/557361"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>0.1%</p></div>
</text>
<entry>
<reference value="Evidence/557363"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>0.2%</p></div>
</text>
<entry>
<reference value="Evidence/557362"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Diabetic ketoacidosis in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>0.17%</p></div>
</text>
<entry>
<reference value="Evidence/557363"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Diabetic ketoacidosis in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557361"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference 0.1% (CI95 0.0% to 0.3%); OR 1.71 (CI95 0.79 to 3.69)</p></div>
</text>
<entry>
<reference value="Evidence/557361"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>High certainty</p></div>
</text>
<entry>
<reference value="Evidence/557361"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of diabetic ketoacidosis.</p></div>
</text>
<entry>
<reference value="Evidence/557361"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313962-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Diabetic ketoacidosis with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Serious hyperglycaemia"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236974"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313963"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Serious hyperglycaemia"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Serious hyperglycaemia</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236974"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313963"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Serious hyperglycaemia"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1 studies, 463 participants</p></div>
</text>
<entry>
<reference value="Evidence/557364"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1%</p></div>
</text>
<entry>
<reference value="Evidence/557366"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1.5%</p></div>
</text>
<entry>
<reference value="Evidence/557365"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Serious hyperglycaemia in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>1.47%</p></div>
</text>
<entry>
<reference value="Evidence/557366"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Serious hyperglycaemia in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557364"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference 0.5% (CI95 -0.2% to 1.9%); OR 1.48 (CI95 0.75 to 2.93)</p></div>
</text>
<entry>
<reference value="Evidence/557364"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>High certainty</p></div>
</text>
<entry>
<reference value="Evidence/557364"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There is no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on the risk of serious hyperglycaemia.</p></div>
</text>
<entry>
<reference value="Evidence/557364"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313963-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Serious hyperglycaemia with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Genital infection"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236977"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313964"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Genital infection"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Genital infection</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236977"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313964"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Genital infection"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>2 studies, 1282 participants</p></div>
</text>
<entry>
<reference value="Evidence/557367"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>5%</p></div>
</text>
<entry>
<reference value="Evidence/557369"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>20.8%</p></div>
</text>
<entry>
<reference value="Evidence/557368"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Genital infection in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>20.83%</p></div>
</text>
<entry>
<reference value="Evidence/557369"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Genital infection in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557367"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference 15.8% (CI95 6.4% to 29.9%); OR 5.0 (CI95 2.45 to 10.2)</p></div>
</text>
<entry>
<reference value="Evidence/557367"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>High certainty</p></div>
</text>
<entry>
<reference value="Evidence/557367"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SGLT2 inhibitors increase the risk of genital infection compared with GLP-1 receptor agonists.</p></div>
</text>
<entry>
<reference value="Evidence/557367"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313964-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Genital infection with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Severe gastrointestinal events"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236980"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313965"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Severe gastrointestinal events"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Severe gastrointestinal events</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236980"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313965"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Severe gastrointestinal events"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>7 studies, 24638 participants</p></div>
</text>
<entry>
<reference value="Evidence/557370"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>4.4%</p></div>
</text>
<entry>
<reference value="Evidence/557372"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>10.2%</p></div>
</text>
<entry>
<reference value="Evidence/557371"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-intervention-idence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Severe gastrointestinal events in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>10.17%</p></div>
</text>
<entry>
<reference value="Evidence/557372"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparator-onidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Severe gastrointestinal events in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>
<reference value="Evidence/557370"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Risk Difference 5.8% (CI95 0.9% to 14.2%); OR 2.46 (CI95 1.22 to 4.97)</p></div>
</text>
<entry>
<reference value="Evidence/557370"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Very low certainty -- Due to serious inconsistency, Due to very serious indirectness, Due to very serious imprecision</p></div>
</text>
<entry>
<reference value="Evidence/557370"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>GLP-1 receptor agonists may increase the risk of severe gastrointestinal events compared with SGLT2 inhibitors.</p></div>
</text>
<entry>
<reference value="Evidence/557370"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-dichotomous-outcome-313965-comparative-eidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Severe gastrointestinal events with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Health-related quality of life"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236983"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109587"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Health-related quality of life"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Health-related quality of life</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236983"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109587"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Health-related quality of life"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No sample size data.]</p></div>
</text>
<entry>🔗
<reference value="Evidence/236984"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>MEAN 51.84 </p></div>
</text>
<entry>
<reference value="Evidence/557374"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>MEAN 51.91 </p></div>
</text>
<entry>
<reference value="Evidence/557373"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-intervention-oidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Health-related quality of life in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[Not a proportion.]</p></div>
</text>
<entry>
<reference value="Evidence/557374"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparator-onlidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Health-related quality of life in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>🔗
<reference value="Evidence/236984"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SMD 0.01 (CI95 -0.19 to 0.2 )</p></div>
</text>
<entry>🔗
<reference value="Evidence/236984"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Low certainty -- Due to very serious imprecision</p></div>
</text>
<entry>🔗
<reference value="Evidence/236984"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There may be no important difference between SGLT2 inhibitors and GLP-1 receptor agonists on health-related quality of life.</p></div>
</text>
<entry>🔗
<reference value="Evidence/236984"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109587-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Health-related quality of life with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
<section>
<title value="Body weight"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary-of-findings-entry-for-a-single-outcome"/>
<display value="Summary of findings entry for a single outcome"/>
</coding>
</code>
<focus>🔗
<reference value="EvidenceVariable/236986"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109588"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Body weight"/>
</focus>
<section>
<title value="Outcome"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="outcome-measure"/>
<display value="Outcome Measure"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Body weight</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236986"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109588"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Body weight"/>
</entry>
</section>
<section>
<title value="Sample Size"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="sample-size"/>
<display value="Sample Size"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>2 studies, 1139 participants</p></div>
</text>
<entry>🔗
<reference value="Evidence/236987"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result Without Treatment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-comparator-alone"/>
<display value="Result with comparator alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>MEAN 86.55 Kg</p></div>
</text>
<entry>
<reference value="Evidence/557376"/>
<type value="Evidence"/>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Observed"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone"/>
<display value="Result with intervention alone"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>MEAN 86.08 Kg</p></div>
</text>
<entry>
<reference value="Evidence/557375"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-intervention-oidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived InterventionOnlyEvidence: Body weight in SGLT2 inhibitors Group in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Result With Treatment--Derived"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-alone-calculated"/>
<display value="Result with intervention alone (calculated)"/>
</coding>
<text
value="result with intervention with calculated value derived from the control group and effect estimate"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[Not a proportion.]</p></div>
</text>
<entry>
<reference value="Evidence/557376"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparator-onlidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived ComparatorOnlyEvidence: Body weight in GLP-1 RA Group in Adults with type 2 diabetes"/>
</entry>
<entry>🔗
<reference value="Evidence/236987"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Effect Estimate"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="result-with-intervention-vs-comparator"/>
<display value="Result with intervention vs. comparator"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>MD -0.47 Kg (CI95 -0.09 Kg to -0.85 Kg)</p></div>
</text>
<entry>🔗
<reference value="Evidence/236987"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Certainty of Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="certainty-of-evidence"/>
<display value="Certainty of Evidence"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Moderate certainty -- Due to serious inconsistency</p></div>
</text>
<entry>🔗
<reference value="Evidence/236987"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
<section>
<title value="Assertion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="assertion"/>
<display value="Assertion"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>SGLT2 inhibitors probably reduce body weight compared with GLP-1 receptor agonists.</p></div>
</text>
<entry>🔗
<reference value="Evidence/236987"/>
<type value="Evidence"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value
value="MAGIC-5288-j1Wqrn-continuous-outcome-109588-comparative-evidence"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display
value="MAGIC-derived Evidence: Body weight with SGLT2 inhibitors vs. GLP-1 RA in Adults with type 2 diabetes"/>
</entry>
</section>
</section>
</section>
<section>
<title value="Groups"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="groups"/>
<display value="Groups"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No narrative text.]</p></div>
</text>
<section>
<title value="Total Group"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="population"/>
<display value="Population"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Intervention Group"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="intervention-group"/>
<display value="Intervention Group"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Comparator Group"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="comparator-group"/>
<display value="Comparator Group"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Group Assignment"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="GroupAssignment"/>
<display value="GroupAssignment"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
</section>
<section>
<title value="Variables (Measures)"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="variables"/>
<display value="Variables"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>[No data.]</p></div>
</text>
<entry>🔗
<reference value="EvidenceVariable/236953"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313956"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: All-cause mortality"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236956"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313957"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Cardiovascular mortality"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236959"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313958"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Nonfatal myocardial infarction"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236962"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313959"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Nonfatal stroke"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236965"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313960"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: End-stage kidney disease"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236968"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313961"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Heart failure"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236971"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313962"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Diabetic ketoacidosis"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236974"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313963"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Serious hyperglycaemia"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236977"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313964"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Genital infection"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236980"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-313965"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Severe gastrointestinal events"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236983"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109587"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Health-related quality of life"/>
</entry>
<entry>🔗
<reference value="EvidenceVariable/236986"/>
<type value="EvidenceVariable"/>
<identifier>
<type>
<text value="FEvIR Linking Identifier"/>
</type>
<system value="https://fevir.net/FLI"/>
<value value="MAGIC-5288-j1Wqrn-109588"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<display value="OutcomeDefinition: Body weight"/>
</entry>
</section>
</Composition>
IG © 2024+ HL7 International / Clinical Decision Support.
Package hl7.fhir.uv.ebm#1.0.0-ballot3 based on FHIR 6.0.0-ballot3.
Generated
2026-06-12
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change